A multivariable prognostic score to guide systemic therapy in early-stage HER2-positive breast cancer: a retrospective study with an external evaluation
Aleix Prat(Hospital Clínic de Barcelona), PierFranco Conte(University of Padua), Bárbara Adamo(Hospital Clínic de Barcelona), Francesco Schettini(Target (United States)), Federica Miglietta(University of Padua), Fara Brasó‐Maristany(Hospital Clínic de Barcelona), Juan Miguel Cejalvo(Universitat de València), Roberto D’Amico(University of Modena and Reggio Emilia), Sònia Pernas, Antonio Llombart‐Cussac(MedSIR (Spain)), Valentina Guarneri(Istituto Oncologico Veneto), Luís Manso(Research Institute Hospital 12 de Octubre), Blanca González‐Farré(Hospital Clínic de Barcelona), Tomás Pascual(Breast Cancer Research Foundation), Giancarlo Bisagni, Loredana Urso(Istituto Oncologico Veneto), Javier Cortés(Villa Maria Hospital), Benedetta Conte(Ospedale Policlinico San Martino), María Vidal(Inserm), Mafalda Oliveira(Vall d'Hebron Institut de Recerca), Joel S. Parker(University of North Carolina at Chapel Hill), Jesús Alarcón(Hospital Universitario Son Espases), Charles M. Perou(University of North Carolina at Chapel Hill), Antonino Musolino(Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori), Antonio Frassoldati(University of Ferrara), Esther Sanfeliu(Hospital Clínic de Barcelona), Laia Paré(Consorci Institut D'Investigacions Biomediques August Pi I Sunyer), Núria Chic(Breast Cancer Research Foundation), Eva Ciruelos(Hospital Universitario 12 De Octubre), Enrico Tagliafico(University of Modena and Reggio Emilia), Patricia Villagrasa, Maria Vittoria Dieci(Istituto Oncologico Veneto), Cristina Saura(Vall d'Hebron Hospital Universitari), Gaia Griguolo(University of North Carolina at Chapel Hill), Alba A. Brandes(Istituto delle Scienze Neurologiche di Bologna), Federico Piacentini(Azienda Unita' Sanitaria Locale Di Modena), Montserrat Muñoz-Mateu(Consorci Institut D'Investigacions Biomediques August Pi I Sunyer), Lisa A. Carey(University of North Carolina at Chapel Hill), Rafael López‐López(Universidade de Santiago de Compostela)
Cited by 75
Related Papers
The Immune Landscape of Cancer
|Immunity|2018|6.2k
Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis
|The Lancet|2014|4.7k
Pembrolizumab for Early Triple-Negative Breast Cancer
|New England Journal of Medicine|2020|3.1k
Breast cancer
|Nature Reviews Disease Primers|2019|2.9k
Immunohistochemical and Clinical Characterization of the Basal-Like Subtype of Invasive Breast Carcinoma
|Clinical Cancer Research|2004|2.7k